CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Inclusion Criteria: * Patients with a history of CD19+ lymphoid malignancy defined as acute lymphoblastic leukemia, acute biphenotypic leukemia, non-Hodgkin's lymphoma, small lymphocytic lymphoma, or chronic lymphocytic leukemia with active disease defined by presence of \> 5% malignant blasts in bone marrow and/or peripheral blood, and/or minimal residual disease by flow cytometry or molecular analysis for fusion proteins, and/or positive imaging for extramedullary disease; patients must have measurable disease at time of study treatment * Confirmed history of CD19 positivity by flow cytometry for malignant cells * Lansky/Karnofsky performance scale \> 60% * Patient able to provide written informed consent; parent or guardian of minor patient able to provide written informed consent * Patient able to provide written informed consent for the long-term follow-up gene therapy study: 2006-0676; parent or guardian of minor patient able to provide written informed consent for the long-term follow-up gene therapy study: 2006-0676 Exclusion Criteria: * Positive beta human chorionic gonadotropin (HCG) in female of child-bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization or lactating females * Patients with known allergy to bovine or murine products * Positive serology for human immunodeficiency virus (HIV) * Active hepatitis B or active hepatitis C * Has received donor lymphocyte infusion (DLI) product within 6 weeks of CAR T cell …